Roche Holding Ltd · SIX:RO
Roche — J.P. Morgan 39th Annual Healthcare Conference 2021
35 slides from Roche's conference presentation, Jan 11, 2021
Slide 1: Strategy, Culture, and Rejuvenation
Strategy, Culture, and Rejuvenation Alan Hippe | CFO J.P.Morgan Healthcare Conference, January 2021
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Agenda
COVID-19: Roche’s contributions Priorities to maintain leadership position Environment, Governance, and Social Responsibility Outlook 3
Slide 4: Roche's response to the pandemic
Roche’s response to the pandemic Potential use cases for Dia/Pharma COVID-19 portfolio Pre-exposure/asymptomatic Symptomatic Post-vaccination (screening and prophylaxis) (diagnosis and treatment) (confirmed protection) PCR Use cases will continue to persist with vaccine rollout Antigen Test Diagnost
Slide 5: Responding quickly and broadly to the pandemic
Responding quickly and broadly to the pandemic Collaboration with Atea on development of AT-527 Pharma Collaboration with Regeneron FDA EUA granted in mild- on REGN-COV2 global supply moderate adults and adolescents COVACTA trial REMDACTA trial COVACTA EMPACTA REMAP-CAP initiated initiated trial res
Slide 6: Increasing testing capacity and installed base
Increasing testing capacity and installed base Installed base Test capacity High throughput cobas 6800/8800 • cobas® SARS-CoV-2 >20m ~1,500-4,000 tests in 24h • cobas® SARS-CoV-2 & Influenza A/B >1,000 per month • Elecsys® Anti-SARS-CoV-2 cobas e411/601/602/801 • Elecsys® Anti-SARS-CoV-2 S ~40,000 ~
Slide 7: Agenda
COVID-19: Roche’s contributions Priorities to maintain leadership position Environment, Governance, and Social Responsibility Outlook 7
Slide 8: Priorities to maintain leadership position
4 Priorities to maintain leadership position Innovation: Diagnostics: Leading personalized Replace & extend the Growing installed base Transformation healthcare revolution business & expanding menu Improve on current Expansion with additional Lead in digitalization & Improve mind-set, standard of ca
Slide 9: Priorities to maintain leadership position
4 Priorities to maintain leadership position Innovation: Diagnostics: Leading personalized Replace & extend the Growing installed base Transformation healthcare revolution business & expanding menu Improve on current Expansion with additional Lead in digitalization & Improve mind-set, standard of ca
Slide 10: New medicines: Replace and extend the business
New medicines: Replace and extend the business Replace/extend existing businesses Entering new franchises Oncology: Immunology: Gazyva, Tecentriq (mUC, HCC, Mel), etrolizumab (CD), Venclexta, tiragolumab, Gazyva (LN), MabThera/Rituxan Polivy, giredestrant (HR+ BC) rhPTX-2 (IPF) mosunetuzumab, inavol
Slide 11: Strong short- and mid-term news flow
Strong short- and mid-term news flow Diversifying the late stage pipeline and setting new standards of care Product Indication Filing Population Product Indication Filing Population tominersen Huntington’s 2022 ~83k RET+ NSCLC filed ~2k (Dx+) Gavreto ~9,300k (prodromal) thyroid cancer filed ~6k (Dx+
Slide 12: Strong replacement power of franchises - Lung Cancer
Strong replacement power of franchises - example of Lung Cancer Early disease, novel combinations, targeted agents Cancer immunotherapy Tecentriq neoadjuvant and adjuvant data in 2021; Tiragolumab BTD in PD-L1 high NSCLC tiragolumab Driver mutations Rare mutations (≤2%) add up to ~10% of the lung ca
Slide 13: Replace and extend current business – Ophthalmology
Replace and extend current business – example Ophthalmology Improve on durability, extend geographical outreach Adherence to IVT therapies is low and infrequent PDS and faricimab have the potential to improve dosing in the real world correlates with vision loss real world outcomes with longer durabi
Slide 14: Investing in external innovations
Investing in external innovations1 Accelerate drug discovery and diagnostic technologies Technology stage at the time of licensing Research technologies Early stage assets Late stage assets Digital & PHC Diagnostics (HBV) (tominersen) (rh-pentraxin-2) (SARS-CoV-2 rapid (gene therapy) (E3 ligases) (m
Slide 15: Innovation driving portfolio rejuvenation
Innovation driving portfolio rejuvenation Increasing share of sales coming from recent launches CHFm % of Pharma Sales Pharma sales mix 15,000 40% 12,000 29% YT D 2019 29% 29% 42% 9,000 21% YT D 2020 40% 29% 31% 6,000 15% 3,000 2024E ~60% ~30% ~10% 0 YTD Sep 2017 YTD Sep 2018 YTD Sep 2019 YTD Sep 20
Slide 16: Launching new medicines in virtual environment
Launching new medicines in virtual environment; example Evrysdi US launch SMA Patients: Health Care Professionals: SMA Community: Evrysdi shipped to patient’s Digital tools and resources to Virtual webinars and social home through contactless educate HCPs and their staff media events in partnership
Slide 17: Priorities to maintain leadership position
4 Priorities to maintain leadership position Innovation: Diagnostics: Leading personalized Replace & extend the Growing installed base Transformation healthcare revolution business & expanding menu Improve on current Expansion with additional Lead in digitalization & Improve mind-set, standard of ca
Slide 18: Role of in-vitro diagnostics
Role of in-vitro diagnostics Playing a foundational role to improve outcomes & lower costs examples IVD influences decisions... ... with tangible value for healthcare systems Early detection/prevention HPV testing ~2% IMPROVE 1h hsTnT algo for acute myocardial of global Timely clinical / right infar
Slide 19: Priorities to maintain leadership position
4 Priorities to maintain leadership position Innovation: Diagnostics: Leading personalized Replace & extend the Growing installed base Transformation healthcare revolution business & expanding menu Improve on current Expansion with additional Lead in digitalization & Improve mind-set, standard of ca
Slide 20: Pharma digital strategic priorities
Pharma digital strategic priorities Clinical Production & Pre-clinic Registration Access Diagnosis Treatment development Supply Research & development Supplementing data & market access Personalization of patient care Single cell and spatial genomics Real World Data as external control Characterizat
Slide 21: Priorities to maintain leadership position
4 Priorities to maintain leadership position Innovation: Diagnostics: Leading personalized Replace & extend the Growing installed base Transformation healthcare revolution business & expanding menu Improve on current Expansion with additional Lead in digitalization & Improve mind-set, standard of ca
Slide 22: Adjusting to a changing environment
Adjusting to a changing environment Initiatives across the entire company/value chain Improve processes & Optimization manufacturing Improving structures & simplify decision taking & logistics processes Clinical Pre-clinic Registration Production & Supply Sales & Marketing development Manufacturing
Slide 23: Strategic re-allocation of resources: example Pharma
Strategic re-allocation of resources: example Pharma Pharma cost structure Principles for resource allocation • Re-allocate resources into R&D while working Cost of sales Cost of sales on and protecting profitability M&D M&D G&A • Optimizing costs and efforts by G&A - More targeted and often virtual
Slide 24: Invest in innovation: Assets in Ph III & registration
Invest in innovation: Assets in Ph III & registration Outlook Strong momentum in the second half 2020 FY 2020 23 2 6 14 13 13 2 2 11 2 2 3 1 10 5 4 5 NMEs 4 4 1 1 1 1 1 1 1 10 1 1 5 5 5 4 4 FY 2016 FY 2017 FY 2018 FY 2019 HY 2020 +10 NMEs to be added in 2H’20 FY 2020 Gavreto in RET+ NSCLC & thyroid
Slide 25: Agenda
COVID-19: Roche’s contributions Priorities to maintain leadership position Environment, Governance, and Social Responsibility Outlook 25
Slide 26: Our impact on society
Our impact on society Roche ranked most sustainable healthcare company by DJSI for the 11 th time Environment Providing a great workplace Access to our products 40% 32% 30% 22% 24% 20% 19% 10% 0% 2014 2015 2016 2017 2018 2019 Women in key leadership roles Key leaders with diverse work experience Goa
Slide 27: Agenda
COVID-19: Roche’s contributions Priorities to maintain leadership position Environment, Governance, and Social Responsibility Outlook 27
Slide 28: Defending margins despite headwinds and investment in innovation
Defending margins despite headwinds and investment in innovation Core operating profit Sales New Product Growth: 40% of sales YTD Sep 20 (up from 29% YTD Sep 19) 40.6% 40.2% % of sales 39.7% Diagnostics: COVID-19 testing Biosimilars / COVID-19: contraction in AHR in 2020 Diagnostics: routine busines
Slide 29: Growing through biosimilar transition
Growing through biosimilar transition Pharma NME and Dia launches Ocrevus, Perjeta, Hemlibra, Tecentriq, Venclexta, Gazyva, Alecensa, Xofluza, Polivy, Rozlytrek, Evrysdi, Enspryng, Gavreto, ipatasertib, tiragolumab, etrolizumab, PDS, faricimab, tominersen, gantenerumab, etc. cobas 6800/8800, cobas 5
Slide 30: Doing now what patients need next
Doing now what patients need next
Slide 31: Growing installed base worldwide driving reagents consumption
Growing installed base worldwide driving reagents consumption Integrated Core Lab +11% cobas 6000/8000 +36% cobas 6800/8800 +17% Connectivity +21% +21% Preanalytics Middleware cobas 4000 +9% 2019 Growth Growth rates being from the period of January 1, 2019 to December 31, 2019 31
Slide 32: Roche-sponsored/partnered trials for COVID-19
Roche-sponsored/partnered trials for COVID-19 Pursuing multiple options to maximize public health impact Pre-exposure Post-exposure Outpatient Hospitalized Hospitalized prophylaxis prophylaxis treatment & mild/moderate Severe high risk pts. COVACTA (Ph 3) X EMPACTA (Ph 3) ✓ Actemra REMDACTA (Ph 3) M
Slide 33: Hematology: redefining the standard of care in B-cell malignancies
Hematology: continuing to redefine the standard of care in B- cell malignancies and expanding into new diseases B-cell malignancies Polivy 1L DLBCL data in 2021; mosun/glofit advanced to randomized Ph 3 trials in NHL New hematologic diseases Venclexta >40% US market share in AML; ongoing Ph 3 trials
Slide 34: Replace and extend franchises: Breast Cancer
Replace and extend franchises: the example of Breast Cancer: Expanding into TNBC and HR+ BC HER2+ BC Phesgo approved in US and EU in 2020 (SC fixed dose combination of Hercptin + Perjeta) HR+/HER2- BC SERD and Pi3K programs advanced to Ph 3 in HR+ BC with large addressable population TNBC Tecentriq
Slide 35: Doing now what patients need next
Doing now what patients need next
Roche Holding — J.P. Morgan 39th Annual Healthcare Conference 2021 on 6ix